{"id":"W2737220576","doi":"10.1200/jco.2013.31.15_suppl.574","title":"Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Toronto; Sunnybrook Health Science Centre; McMaster University; Grand River Hospital; Ottawa Hospital; BC Cancer Agency; Health Sciences Centre; Ontario Clinical Oncology Group; University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; N-terminal telopeptide; Placebo; Bone remodeling; Gastroenterology; Vandetanib; Fulvestrant; Breast cancer; Oncology; Urology; Endocrinology; Cancer; Estrogen receptor; Pathology; Receptor; Osteocalcin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008689499,0.000593818,0.01088775,0.0004823357,0.00009050779,0.0000201539,0.0002845596,0.0003445381,0.001239957],"category_scores_gemma":[0.002449098,0.000329905,0.0006248206,0.0004801504,0.0009597,0.0004775134,0.00009111355,0.001588056,0.000008502156],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001057411,"about_ca_system_score_gemma":0.006822299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003611722,"about_ca_topic_score_gemma":0.0002809496,"domain_scores_codex":[0.9877896,0.002898177,0.006908539,0.000547124,0.001074659,0.0007819037],"domain_scores_gemma":[0.9842143,0.007018833,0.006269708,0.0004075139,0.001301611,0.0007880171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8904309,0.02563962,0.0001198636,0.00004489948,0.00577399,0.001641677,0.002337709,0.00006775845,0.00274305,0.000007950653,0.0001332916,0.07105928],"study_design_scores_gemma":[0.8276131,0.1618001,0.002273008,0.0003279845,0.002597273,0.001969507,0.002624536,0.0001610626,0.00004382086,0.0001240478,0.0001802994,0.0002853151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820804,0.001383338,0.0002873723,0.004015795,0.0008220334,0.01117266,0.00006939799,0.00001966254,0.0001493278],"genre_scores_gemma":[0.9916905,0.0009677034,0.003885079,0.0005954591,0.0009629298,0.001140096,0.000005617282,0.00007840818,0.00067417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1361604,"threshold_uncertainty_score":0.9999153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04259018693465635,"score_gpt":0.416951622254952,"score_spread":0.3743614353202956,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}